Introduction
Thrombotic microangiopathies represent a distinct group within the spectrum of thrombotic disorders, clinically characterized by schistocytic hemolytic Thrombotic microangiopathies are life-threatening disorders characterized by vascular microthromboses, schistocytic hemolytic anemia, and thrombocytopenia. Although recent research has partially explained the pathogenesis of these rare entities, the determinants contributing to the onset and modulating the severity of thrombotic microangiopathies are largely unknown. The present study assessed the putative role of prothrombotic platelet receptor polymorphisms in thrombotic microangiopathies that have been found to be associated with premature onset of myocardial infarction in predisposed individuals. Thirty-four consecutive patients admitted with the diagnosis of thrombotic microangiopathy and 759 healthy subjects were enrolled. Genotyping of the human platelet antigen (HPA) 2 an the Kozak sequence polymorphism of GP Ibα of the platelets' von Willebrand factor receptor glycoprotein (GP) Ib-V-IX, the HPA-1 and the HPA-3 polymorphism of the fibrinogen receptor GP IIb-IIIa (integrin α IIb β 3 ) and the HPA-5 and GP Ia 807 C/T polymorphism of the collagen receptor GP Ia-IIa (integrin α 2 β 1 ) were determined according to standard procedures. As a result, no significant differences in the prevalence of prothrombotic variants of platelet-receptor polymorphisms between patients and healthy control subjects were observed. However, although not significant, the prothrombotic bb genotype of the HPA-1 polymorphism was more prevalent in the patients. The findings do not provide evidence that platelet receptor polymorphisms are determinants for the onset of thrombotic microangiopathies or predispose to a more severe course. Along with this observation, screening for respective platelet-receptor polymorphisms does not appear to contribute to risk stratification of affected patients. Keywords: thrombotic microangiopathies; platelet receptor polymorphisms factors H and I, endogenous pathogenic risk factors for the onset of these rare thrombotic disorders remain unclear in the majority of affected patients. 3 Because thrombotic microangiopathies represent a group of thrombotic disorders, it is likely that inherited risk factors associated with (1) venous thromboembolism and/or (2) arterial vascular complications might also play a role in this clinical setting. Although this aspect has not yet been extensively studied, the results from recent studies suggest a potential role of inherited thrombophilic risk factors, such as the G1691A mutation in the factor V gene ("factor V Leiden"), for the onset of these rare thrombotic disorders. 4, 5 Recently, we identified the GG genotype of the G1642A polymorphism of the thrombin-activatable fibrinolysis inhibitor (TAFI), an important regulator at the interface of fibrinolysis and inflammation, and the homozygous Leu variant of the factor XIII Val34Leu polymorphism as another factor predisposing to the onset of thrombotic microangiopathies. 6 In the presented study, we focused on the potential role of prothrombotic variants of platelet receptor polymorphisms in the pathogenesis of thrombotic microangiopathies. Respective polymorphisms of platelet receptors involved in platelet adhesion and aggregation were shown to modulate platelet thrombogenicity in vitro and in vivo. Consequently, carriers of prothrombotic variants were shown to have an increased risk for premature onset of events in the arterial vasculature, particularly acute coronary syndromes. [7] [8] [9] [10] Because thrombotic microangiopathies are characterized by localization of the thrombotic event in the arterial microvasculature, we hypothesized that prothrombotic platelet receptor variants would predispose for the onset of these rare thrombotic disorders.
To test our hypothesis, a variety of platelet receptor polymorphisms known to modulate platelet thrombogenicity were analyzed (Table 1 ). These polymorphisms involve the platelet fibrinogen receptor, glycoprotein (GP) IIb-IIIa (integrin α IIb β 3 ), the platelet von Willebrand factor receptor GP Ib-V-IX, and one of the platelets' collagen receptors, GP Ia-IIa (integrin α 2 β 1 ).
Patients and Methods

Subjects
We studied 51 consecutive patients of Caucasian origin (41 women, 10 men; mean age [± SD] 41 ± 13 years; range 17-68 years) with the diagnosis of thrombotic microangiopathy. All patients were recruited from the Department of Nephrology, Heinrich Heine University Medical Center, Düsseldorf, Germany, between 2003 and 2007. Diagnosis was based on established clinical criteria, in particular (1) schistocytic-hemolytic anemia (hemoglobin <12 g/dL), (2) platelet count <100 000/μL, and (3) organ dysfunction without alternative explanation. 1, 2 Additional laboratory parameters such as deficiency of the von Willebrand factor cleaving protease ADAMTS 13 or an elevation of the lactate dehydrogenase (LDH) were not employed as diagnostic criteria.
As controls, 759 healthy subjects of Caucasian origin (426 women, 333 men; mean age [± SD] 36 ± 12 years) without a history of previous arterial or venous thromboembolism were recruited by the Heinrich Heine University Blood Donation Center, Düsseldorf, Germany. These normal individuals were from the same geographic region as the patients but unrelated to them. The study was performed in accordance with the Helsinki Declaration and written informed consent was obtained.
Laboratory Tests
Genomic DNA was extracted from peripheral blood leukocytes using the Chelex system (BioRad, Munich, Germany) or the Qiagen system (Qiagen, Hilden, Germany). Molecular genetic analysis was performed using a LightCycler as previously described to determine platelet-receptor polymorphisms of the fibrinogen receptor GP IIb-IIIa (HPA-1, HPA-3), the von Willebrand factor receptor GP Ib-V-IX (HPA-2, Kozak polymorphism), and the collagen receptor GP Ia-IIa (C807T, HPA-5). [11] [12] [13] [14] [15] [16] 
Statistical Analysis
From the prevalences of respective receptor polymorphisms in patients with thrombotic microangiopathies and healthy control subjects, odds ratios and confidence intervals at the 95% level were calculated. Differences in proportions were tested by the Fisher's exact test. Statistical significance was assumed at a P-value below .05. To rule out an influence of inhomogeneous composition of patients and controls, the crude results were adjusted for age and gender using a logistic regression analysis. All statistical analyses were performed using the SAS software (version 8.2, SAS Institute Inc., Cary, NC).
Results
The prevalences obtained for the different genotypes of polymorphisms of GP IIb-IIIa (HPA-1, HPA-3), GP Ib-V-IX (HPA-2, Kozak polymorphism), and GP Ia-IIa (HPA-5, GP Ia 807 C/T polymorphism) are given in Table 2 .
From the prevalences of prothrombotic genotypes and genotypes including a prothrombotic allele relative risks (odds ratios) and exact confidence intervals calculated at the 95% level are given. Results after adjustment for age and gender including respective P-values are given in Table 3 . Although no significant differences in the distribution of prothrombotic genetic variants were observed, elevated relative risks (defined as odds ratios [OR] ≥2.5) were found for some genetic variants, suggesting a potential role as factor predisposing to the manifestation of thrombotic microangiopathies: according to this definition, the HPA-1b/1b genotype of GP IIb-IIIa (OR 2.68, 95% confidence interval [CI] 0.49-9.7, P = .1306) and the HPA-2b/2b genotype (OR 3.04, CI 0.06-31.41, P = .33) appear to be the most promising candidate variants for further investigations.
Sample size calculations could not be performed for this pilot study. On the basis of the actual results of genotype distributions in patients with thrombotic microangiopathies and healthy control subjects, however, sample size calculations could be performed for future studies to yield a desired statistical power of 0.8 and a P-value below .05 for the actual ratios of patients to healthy control subjects and a suggested equal number of patients and controls (Table 4 ). For the candidate genetic variants HPA-1b/1b, HPA-2b/2b, CC genotype of the Kozak sequence polymorphism of GP Ib-V-IX, and HPA-5b/5b patient numbers of 239, 589, 822, and 1281 would be needed for the current patient/control ratio, whereas an equal number of patients and controls would require case numbers of 845, 1340, 1701, and 2683, respectively.
Discussion
This is the first clinical study addressing the putative role of prothrombotic genetically determined variants of platelet receptor polymorphisms for the pathogenesis of thrombotic microangiopathies. Although no statistically significant results were obtained, increased relative risks (expressed as OR > 2.5) suggest a possible influence of the prothrombotic bb-genotypes of the human platelet antigen-1 (HPA-1) and HPA-2 for the onset of these rare thrombotic disorders. By contrast, an influence of other prothrombotic variants of genetically determined polymorphisms addressed in this study on the manifestation of thrombotic microangiopathies appears to be rather unlikely according to our results. The 1b/1b-genotype and the 1a/1b-genotype of the HPA-1 polymorphism of GP IIb-IIIa have been reported to be associated with premature thrombotic events in the arterial vasculature, as previously demonstrated by different groups. 7, Evidence for a prothrombotic effect of the HPA-1b variant of GP IIb-IIIa comes from studies performed in patients with coronary heart disease and myocardial infarction. As demonstrated previously, the prevalence of the prothrombotic HPA-1b allele is higher in patients with myocardial infarction due to coronary heart disease compared with those with asymptomatic coronary heart disease. 7 In addition, patients suffering from bypass occlusion, myocardial infarction or death after coronary artery bypass grafting have a higher prevalence of the HPA-1 b allele compared to patients without these complications (OR 4.7). 18 Thus, the HPA-1b allele has been identified as a genetically determined risk factor for premature myocardial infarction in predisposed individuals suffering from coronary heart disease but not a risk factor of coronary heart disease itself. 8 Compared with the results obtained for carriers of the HPA-1 b allele, the data concerning the role of the b-allele of the HPA-2 polymorphism for the manifestation of arterial thrombosis are sparse. However, results from the Helsinki Sudden Death Study, which comprised two large autopsy series, suggest that the HPA-2b allele displays a risk factor for coronary thrombosis, fatal myocardial infarction, and sudden cardiac death. 20 A further study demonstrated that carriers of the HPA-2 b allele might also have an increased risk for cerebral vascular disease, but not for venous thrombosis. 21 The results of this pilot study suggest a weak association of the homozygous 1b genotypes of the HPA-1 and the HPA-2 polymorphism with the association of thrombotic microangiopathies. Because the thrombotic event in thrombotic microangiopathies is located in the arterial microvasculature, this association is plausible and mirrors the prothrombotic effect of polymorphisms of platelet receptors involved in platelet adhesion and aggregation in arteriosclerotic vascular disease. However, the association is only weak, making prothrombotic platelet receptor polymorphisms only one weak risk determinant in the complex pathogenesis of thrombotic microangiopathies. Altogether, the pathogenesis of these rare thrombotic disorders involves multiple pathogenetic processes that, together, lead to the manifestation of thrombotic microangiopathies. As proposed, endothelial cell activation due to a triggering process is the initial key event in the pathogenetic process, resulting in activation of hemostasis and enhanced inflammatory response. Altogether, these processes result in a prothrombotic state, leading to microvascular thrombosis and, finally, the manifestation of thrombotic microangiopathies in predisposed individuals. Notably, the power of the current pilot study is low and the overrepresentation of the prothrombotic HPA-1b/1b and HPA-2b/2b genotypes was not statistically significant. Because the genotype distributions of respective prothrombotic platelet receptor polymorphisms in patients with thrombotic microangiopathies were not known when planning this pilot study, sample size calculations could not be performed. Based on our results, sample size calculations for future studies were performed. According to the current data, 239 and 589 patients would be needed, respectively, to gain a sufficient statistical power of 0.8 regarding the role of the HPA-1b/1b and the HPA-2b/2b variants for the onset of thrombotic microangiopathies, when using an identical ratio of patients to controls as in our study. This number would further increase to 845 and 1340 patients, respectively, when an equal number of patients and controls would have to be investigated. These data show that statistically significant data regarding the role of prothrombotic platelet receptor polymorphisms for the onset of thrombotic microangiopathies can only be obtained in a multicentre approach, considering the low prevalence of thrombotic microangiopathies of estimated 1 in 1 000 000.
This study has been performed in a German population. Given the well-known differences in genotype distributions of platelet receptor polymorphisms in different ethnic populations, 22 different results could be obtained in studies conducted in other geographical regions. Thus, geographical differences in genotype distributions have to be considered when our results are compared with future studies addressing the same issue.
Altogether, our current pilot study shows that prothrombotic platelet receptor polymorphisms do not have a major contributory role on the manifestation of thrombotic microangiopathies. However, because the genotypes HPA-1b/1b and HPA-2b/2b show an OR > 2.5 larger number of patients may show a significant difference. To clarify this hypothesis, large multicenter trials are necessary to obtain a sufficient number of patients suffering from these rare thrombotic disorders.
